Keyphrases
Anemia
25%
Anti-SARS-CoV-2 Neutralizing Antibody
16%
Anticoagulants
19%
BCR-ABL
18%
Bone Marrow Biopsy
22%
Cancer Epidemiology
16%
Cancer Patients
22%
Characteristic Response
18%
Chronic Myeloid Leukemia
100%
Chronic Phase
32%
Clinical Characteristics
19%
Clinical Survival
16%
Complete Blood Count
22%
Complete Hematologic Response
18%
Complete Remission
49%
COVID-19
45%
COVID-19 Infection
18%
COVID-19 Patients
33%
Cyclophosphamide
29%
D-dimer
17%
Demographic Characteristics
19%
Developing Countries
19%
Diffuse Large B-cell Lymphoma (DLBCL)
50%
European Society for Medical Oncology
16%
General Hospital
25%
Hematological Response
20%
Hemoglobin Level
20%
Hospitalized Patients
22%
Imatinib
36%
Indonesia
71%
Indonesian
52%
Jakarta
38%
Length of Stay
21%
Leukemia Patients
48%
Leukocytes
24%
Multiple Myeloma
25%
Patient Management
20%
Philadelphia Chromosome
21%
Poor Prognosis
19%
Referral Hospital
33%
S-RBD IgG
19%
Single Center
19%
Spike Receptor Binding Domain
16%
Splenomegaly
34%
Tertiary Hospital
33%
Treatment Response
27%
Tyrosine Kinase Inhibitor
21%
Tyrosine Kinase Inhibitor Therapy
16%
Young Males
21%
β-Thalassemia (β-thal)
20%
Medicine and Dentistry
Acute Myeloid Leukemia
16%
Amputation
16%
Anemia
23%
Bendamustine
16%
Beta Thalassemia
20%
Bone Marrow Biopsy
22%
Brentuximab Vedotin
16%
Cancer Epidemiology
16%
Cancer Registry
16%
CD20
20%
Chemoimmunotherapy
16%
Chromosome Aberration
16%
Chronic Myelogenous Leukemia
83%
Chronic Neutrophilic Leukemia
16%
Classical Hodgkin Lymphoma
16%
COVID-19
50%
Diffuse Large B-Cell Lymphoma
54%
Diseases
20%
Follicular Lymphoma
16%
Health Care Cost
16%
Hepatosplenic T-Cell Lymphoma
16%
Hospital-Based Palliative Care
16%
Ileocecal Intussusception
16%
Imatinib
26%
Immunohistochemistry
17%
Induction Chemotherapy
16%
Intussusception
16%
Leukocyte
16%
Leukostasis
16%
Limb Salvage
16%
Lymphadenopathy
17%
Malignant Neoplasm
27%
Medical Oncology
25%
Multiple Myeloma
23%
Myeloid Leukemia
23%
Osteosarcoma
16%
Pancytopenia
16%
Patient Referral
33%
Philadelphia 1 Chromosome
16%
Plasmacytoma
16%
Priapism
16%
Primary Mediastinal B-Cell Lymphoma
16%
Pulmonary Embolism
16%
Rituximab
26%
Splenomegaly
56%
Spontaneous Remission
16%
Symptomatic Treatment
16%
Treatment Response
27%
Tyrosine-Kinase Inhibitor
35%
Uterine Cancer
16%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
16%
Afatinib
16%
Anemia
20%
Anticoagulant Agent
20%
Beta Thalassemia
16%
Brentuximab Vedotin
16%
Cancer Epidemiology
16%
Cancer Registry
16%
Chemotherapy
34%
Chromosome Aberration
16%
Chronic Myeloid Leukemia
50%
Classical Hodgkin Lymphoma
16%
Comorbidity
9%
Coronavirinae
33%
COVID-19 Vaccine
16%
Creatinine
6%
Cross-Sectional Study
8%
Cyclophosphamide
16%
D Dimer
8%
Diseases
53%
Drug Resistance
7%
Epidermal Growth Factor Receptor
16%
Erlotinib
10%
Gefitinib
10%
Imatinib
37%
Infection
23%
Liver Cirrhosis
6%
Lung Embolism
19%
Lupus Erythematosus Nephritis
16%
Malignant Neoplasm
40%
Messenger RNA
16%
Monotherapy
12%
mRNA Vaccine
16%
Multiple Myeloma
7%
Mycophenolate Mofetil
16%
Myeloid Leukemia
23%
Non Small Cell Lung Cancer
16%
Overall Survival
8%
Philadelphia 1 Chromosome
15%
Plasmacytoma
16%
Procalcitonin
6%
Protein Tyrosine Kinase Inhibitor
45%
Remission
30%
SARS Coronavirus
9%
Second-Line Chemotherapy
8%
Side Effect
12%
Splenomegaly
25%
Thalassemia
12%
Vaccine Efficacy
16%
Venous Thromboembolism
16%
